ZLDPY (Zealand Pharma AS) FFO


ZLDPY Zealand Pharma AS ZLDPY
44 GF Score
Price $9.31
GF Value $394.35
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Zealand Pharma AS FFO?

FFO (Funds from operations) only applies to REITs.

ZLDPY
44GF Score
Zealand Pharma AS ZLDPY
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zealand Pharma AS (ZLDPY) Overvalued in 2026?

Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued. The current stock price of $9.31 is trading 97.6% below its estimated GF Value™ of $394.35. GuruFocus considers Zealand Pharma AS to be Possible Value Trap.

Key valuation signals for ZLDPY:

  • FFO:
  • GF Value™: $394.35 vs. price of $9.31 (97.6% below fair value)
  • GF Score™: 44/100 with 3 warning signs

No single metric tells the full story. See the ZLDPY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zealand Pharma AS Business Description

Address Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
44GF Score

Get the complete analysis for ZLDPY

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.31
Price
$394.35
GF Value